| Article ID | Journal | Published Year | Pages | File Type | 
|---|---|---|---|---|
| 3979344 | Bulletin du Cancer | 2011 | 8 Pages | 
Abstract
												Our results suggest that trastuzumab concurrently with WBRT may have a potential clinical impact with low toxicity. Although promising, these preliminary data warrant further validation of trastuzumab as radio sensitizer for WBRT in brain metastases from breast cancer in the setting of a clinical trial. Larger prospective studies are needed to confirm these results.
											Related Topics
												
													Health Sciences
													Medicine and Dentistry
													Oncology
												
											Authors
												Hind Riahi Idrissi, Cyrus Chargari, Marc A. Bollet, Romuald Le Scodan, Liliane Olivier, Thierry Dorval, Virginie Marchand, Paul Cottu, Véronique Dieras, François Campana, Alain Fourquet, Youlia M. Kirova, 
											